Salidroside protects against diabetes-induced cardiac dysfunction by modulating the mechanistic target of rapamycin (mTOR), AMPK, and AKT/heme oxygenase-1(HO-1) signaling pathways (Hao et al., 2021; Ni et al., 2021), (Table 4). The gene discussed is MTOR; the disease is diabetes mellitus.